Dr. Lal PathLabs Limited (LALPATHLAB) AI Stock Analysis

• Market Cap: ₹234.38B
• Dividend Yield: 0.89%
• Average Volume (3M): 3.61K
• Price to Earnings (P/E): 44.1
• Beta (1Y): 0.69
• Revenue Growth: 10.80%
• EPS Growth: 32.79%
• Country: IN
• Employees: 4,099
• Sector: Healthcare
• Sector Strength: 45
• Industry: Medical - Diagnostics & Research
• EPS (TTM): 6.70
• Shares Outstanding: 167,555,020
• 10 Day Avg. Volume: 2,182
• 30 Day Avg. Volume: 3,614
• PEG Ratio: 1.15
• Price to Book (P/B): 9.21
• Price to Sales (P/S): 8.13
• P/FCF Ratio: 38.16
• Enterprise Value/Market Cap: N/A
• Enterprise Value/Revenue: N/A
• Enterprise Value/Gross Profit: N/A
• Enterprise Value/Ebitda: N/A
• 1Y Price Target: ₹1,577.00
• Price Target Upside: 7.06% Upside
• Rating Consensus: Hold
• Number of Analyst Covering: 1
• EPS Forecast (FY): 30.53
• Revenue Forecast (FY): ₹27.36B

• Rating: 66 Neutral
• Price Target: ₹1,511.00 ▲(2.58% Upside)
• Action: Reiterated Date: 11/01/25
• Date: Action: Reiterated 11/01/25

Dr. Lal PathLabs' strong financial performance is the primary driver of its stock score, reflecting robust revenue growth and efficient cash management. However, the technical analysis indicates neutral to bearish momentum, and the high P/E ratio suggests overvaluation, which tempers the overall score.

Positive Factors

High profit margins

Sustained gross (~60.8%) and net (~19.8%) margins indicate durable pricing power, efficient lab operations, and favorable test mix. These margins support reinvestment, buffer demand swings, and enable long-term profitability even as volumes vary, strengthening cash returns to stakeholders.

Strong cash generation

Consistent operating cash flow that aligns with net income and growing free cash flow shows the business converts earnings into real liquidity. This underpins sustained capex funding, potential buybacks/dividends, and financial flexibility to invest in network expansion or weather downturns.

Conservative balance sheet

A low leverage profile and high equity financing reduce refinancing risk and support investment optionality. This conservative structure gives management the capacity to pursue M&A or organic expansion without stressing liquidity, preserving long-term solvency and strategic flexibility.

Negative Factors

ROE needs improvement

A noted shortfall in return on equity suggests capital is not being converted into shareholder returns as efficiently as peers. Over the medium term, improving asset utilization, mix of higher-margin services, or better capital allocation will be needed to lift long-term investor returns.

Moderate revenue growth

Revenue growth around 10.8% is respectable but modest for a healthcare services leader. In a market where scale and faster market share gains matter, this pace may constrain long-term margin expansion and limit returns unless complemented by higher-margin service mix or faster geographic penetration.

Network and capex intensity

Reliance on a physical network of labs and collection centers makes scaling capital intensive and operationally complex. Sustained expansion requires material capex and logistics spending, which can compress returns and slow margin improvement if utilization or density gains lag expectations.

Dr. Lal PathLabs Limited Business Overview & Revenue Model

Company Description

Dr. Lal PathLabs Limited provides diagnostic and related healthcare tests and services in India and internationally. It operates laboratories for carrying the pathological investigations of various branches of bio-chemistry, hematology, histopathology, microbiology, electrophoresis, immuno-chemistry, immunology, virology, cytology, and other pathological and radiological investigations. The company also offers lab staff training; technical; and lab management services. As of March 31, 2022, the company had 277 clinical laboratories, including National Reference Lab at Delhi and Regional Reference Lab at Kolkata; and 4,731 patient service centers and 10,599 pick-up points. Dr. Lal PathLabs Limited was founded in 1949 and is based in Gurugram, India.

How the Company Makes Money

Dr. Lal PathLabs generates revenue primarily through the provision of diagnostic testing services to patients and healthcare institutions. The company earns money by charging fees for a wide array of laboratory tests and health check-up packages. Key revenue streams include individual test requests from patients, partnerships with hospitals and clinics that outsource their diagnostic needs, and corporate tie-ups for employee health check-ups. Additionally, LALPATHLAB benefits from its strong brand reputation and extensive network, which drives patient traffic and enhances customer loyalty. The company also explores opportunities in the telemedicine space and at-home sample collection services, which further contribute to its earnings.

Dr. Lal PathLabs Limited Financial Statement Overview

Summary

Dr. Lal PathLabs exhibits a strong financial position with significant revenue and profit growth, supported by efficient operational margins and a stable balance sheet. The company's cash flow performance underscores its ability to generate and manage cash effectively, ensuring financial flexibility.

Income Statement

Dr. Lal PathLabs showed strong financial performance with a consistent increase in total revenue over the years, marking a significant growth rate from 2024 to 2025. The company enjoys robust profit margins with a gross profit margin of approximately 60.8% and a net profit margin of about 19.8% in the latest year. Both EBIT and EBITDA margins indicate healthy operational efficiency, demonstrating the company's ability to convert revenue into profits effectively.

Balance Sheet

The company maintains a solid financial structure with a low debt-to-equity ratio, indicating conservative leverage. The equity ratio is strong, suggesting a high level of equity financing relative to assets. However, the return on equity shows room for improvement, reflecting moderate efficiency in generating returns for shareholders. The overall balance sheet displays stability and low-risk financial management.

Cash Flow

The cash flow statement reveals a positive trajectory in operating cash flow, aligning well with net income and showcasing strong cash-generating capabilities. Free cash flow has grown significantly, highlighting efficient capital expenditure management and prudent cash utilization. Despite some fluctuations in investing and financing cash flows, the company demonstrates an ability to maintain liquidity and support its growth strategies.

Breakdown	TTM	Mar 2025	Mar 2024	Mar 2023	Mar 2022	Mar 2021
Income Statement
Total Revenue	25.29B	24.61B	22.27B	20.17B	20.87B	15.81B
Gross Profit	14.67B	14.24B	12.79B	11.25B	11.68B	8.77B
EBITDA	6.91B	6.58B	5.67B	4.41B	5.19B	3.99B
Net Income	5.13B	4.87B	3.58B	2.39B	3.45B	2.92B
Balance Sheet
Total Assets	0.00	27.17B	24.56B	23.86B	23.53B	16.61B
Cash, Cash Equivalents and Short-Term Investments	11.64B	11.65B	9.43B	8.14B	6.82B	9.84B
Total Debt	0.00	1.57B	2.47B	4.20B	5.32B	1.50B
Total Liabilities	-22.06B	5.10B	5.71B	6.86B	8.10B	3.85B
Stockholders Equity	22.06B	21.73B	18.49B	16.66B	15.08B	12.45B
Cash Flow
Free Cash Flow	0.00	5.25B	4.84B	4.11B	-294.49M	3.39B
Operating Cash Flow	0.00	5.69B	5.35B	4.56B	4.47B	3.98B
Investing Cash Flow	0.00	-3.03B	-242.69M	-2.87B	-4.49B	-2.12B
Financing Cash Flow	0.00	-3.34B	-4.14B	-2.83B	1.36B	-1.39B

Dr. Lal PathLabs Limited Technical Analysis

• Technical Analysis Sentiment: Negative
• Last Price: 1472.95
• 50DMA: Negative
• 100DMA: Negative
• 200DMA: Negative
• MACD: Positive
• RSI: Neutral
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For IN:LALPATHLAB, the sentiment is Negative. The current price of 1472.95 is above the 20-day moving average (MA) of 1417.99, above the 50-day MA of 1418.74, and below the 200-day MA of 1497.81, indicating a bearish trend. The MACD of -4.67 indicates Positive momentum. The RSI at 45.37 is Neutral, neither overbought nor oversold. The STOCH value of 45.71 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for IN:LALPATHLAB.

Dr. Lal PathLabs Limited Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
VIJAYA	75 Outperform	₹103.11B	64.65	―	0.20%	16.71%	13.92%
THYROCARE	69 Neutral	₹62.83B	45.61	―	0.68%	22.36%	52.00%
JLHL	67 Neutral	₹82.39B	43.68	―	0.14%	18.40%	7.30%
LALPATHLAB	66 Neutral	₹234.38B	44.12	―	0.89%	10.80%	32.79%
KRSNAA	62 Neutral	₹20.57B	25.53	―	0.38%	11.51%	21.56%
METROPOLIS	61 Neutral	₹98.65B	58.60	―	0.21%	15.41%	5.93%
Sector *	51 Neutral	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%

Dr. Lal PathLabs Limited Corporate Events

Dr. Lal PathLabs Doubles Equity Capital with 1:1 Bonus Share Allotment

Dr. Lal PathLabs Limited has allotted 83,775,510 fully paid-up bonus equity shares of face value ₹10 each to its eligible shareholders in a 1:1 ratio, meaning one new share for every existing share held as of the record date of December 19, 2025. Following this bonus issue, the company’s paid-up equity share capital has doubled to ₹167.55 crore, divided into 16,75,51,020 fully paid-up equity shares, with the newly issued bonus shares ranking pari passu with the existing ones; the move broadens the company’s equity base and is likely aimed at enhancing liquidity and rewarding existing shareholders without altering their proportional ownership.

Dr. Lal PathLabs Announces 1:1 Bonus Share Issue

Dr. Lal PathLabs Limited has announced that it will issue bonus equity shares to its members in a 1:1 ratio, meaning one new share for every existing share held. The record date for determining eligibility for these bonus shares is set for December 19, 2025, with the allotment date scheduled for December 22, 2025. This move is likely to enhance shareholder value and reflects the company’s strong financial position and commitment to rewarding its stakeholders.

Dr. Lal PathLabs Announces Postal Ballot Results and New Employee Stock Plan

Dr. Lal PathLabs Limited has announced the results of a postal ballot, where shareholders approved several resolutions, including the implementation of the ‘Dr. Lal PathLabs Employee Restricted Stock Unit Plan 2025’ and the issuance of bonus equity shares. These resolutions are expected to enhance employee engagement and potentially improve the company’s market position by aligning employee incentives with company performance.

Dr. Lal PathLabs Increases Authorized Share Capital to INR 200 Crore

Dr. Lal PathLabs Limited has announced an amendment to its Memorandum of Association (MOA) following approval from its members via a postal ballot. The amendment involves an increase in the company’s authorized share capital from INR 107.96 crore to INR 200 crore, which is expected to enhance the company’s financial capacity and potentially support future growth initiatives.